BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Announces Chief Financial Officer Transition

CVRx (CVRX)CVRxCommercial

MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Jared Oasheim,

Related news

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

RYTMRhythm Pharmaceuticals2026-08-04 20:01 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

IARTIntegra LifeSciences2026-06-23 12:00 EST

Integra LifeSciences Announces Key Executive Appointments

XAIRBeyond Air2026-06-01 12:00 EST

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

ADPTAdaptive Biotechnologies2026-05-29 11:30 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

HYPRHyperfine2026-07-01 12:15 EST

Hyperfine Announces European Launch of Next-Generation Swoop® System

STIMNeuronetics2026-07-20 20:05 EST

Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

RXSTRxSight2026-07-15 20:15 EST

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

CVRXCVRx2026-06-09 11:30 EST

CVRx Announces Chief Financial Officer Transition

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Stock data

Close
5.94 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States